The Experts below are selected from a list of 330 Experts worldwide ranked by ideXlab platform
Frieder Berr - One of the best experts on this subject based on the ideXlab platform.
-
positron emission tomography with 18f fluoro 2 deoxy d glucose for diagnosis and staging of Bile Duct cancer
Hepatology, 2001Co-Authors: Regine Kluge, Frank Schmidt, Karel Caca, Henryk Barthel, Swen Hesse, Peter Georgi, Anita Seese, Dominik Huster, Frieder BerrAbstract:Malignant tumors with high glucose metabolic rates accumulate [18F]-fluorodeoxyglucose (FDG), a positron emitting tracer. The aim of this study was to evaluate FDG positron emission tomography (PET) for detection and staging of human cholangiocarcinoma (CC). Patients with adenocarcinoma of the biliary tree (n = 26), with benign lesions of the Bile Ducts (n = 8), and 20 control patients underwent FDG-PET (370 MBq [18F]-FDG, Siemens ECAT EXACT HR+). In a blinded fashion, 4 independent experts evaluated the PET scans visually and semiquantitatively using the standardized uptake value and a tumor/non-tumor ratio. All adenocarcinomas and benign lesions (sclerosing cholangitis, Bile Duct Adenoma, Caroli's disease) were histologically proven and imaged by magnetic resonance imaging and endoscopic retrograde cholangioscopy. True-positive PET scans were obtained in 24 of 26 CC and false-negative scans in the other 2 (sensitivity 92.3%). The PET scan was true-negative in 18 of 20 controls and in all 8 benign biliary lesions (specificity 92.9%). Visual and semiquantitative evaluation using tumor/non-tumor ratios were equally accurate (accuracy 92.6%) whereas evaluation by standardized uptake value revealed lower accuracy (P < .05). Regional or hepatoduodenal lymph node metastases were detected with PET in only 2 of 15 cases whereas distant metastases (peritoneal carcinomatosis, pulmonary metastases) were diagnosed in 7 of 10 cases. In conclusion, PET is highly sensitive and specific for the detection and localization of CC. It can be helpful for diagnosis of distant metastases but is not suitable for detection of regional lymph node metastases. (HEPATOLOGY 2001;33:1029-1035.)
-
positron emission tomography with 18f fluoro 2 deoxy d glucose for diagnosis and staging of Bile Duct cancer
Annual Meeting of the American Gastroenterological Association, 2001Co-Authors: Regine Kluge, Frank Schmidt, Karel Caca, Henryk Barthel, Swen Hesse, Peter Georgi, Anita Seese, Dominik Huster, Frieder BerrAbstract:Malignant tumors with high glucose metabolic rates accumulate [18F]-fluorodeoxyglucose (FDG), a positron emitting tracer. The aim of this study was to evaluate FDG positron emission tomography (PET) for detection and staging of human cholangiocarcinoma (CC). Patients with adenocarcinoma of the biliary tree (n = 26), with benign lesions of the Bile Ducts (n = 8), and 20 control patients underwent FDG-PET (370 MBq [18F]-FDG, Siemens ECAT EXACT HR + ). In a blinded fashion, 4 independent experts evaluated the PET scans visually and semiquantitatively using the standardized uptake value and a tumor/non-tumor ratio. All adenocarcinomas and benign lesions (sclerosing cholangitis, Bile Duct Adenoma, Caroli's disease) were histologically proven and imaged by magnetic resonance imaging and endoscopic retrograde cholangioscopy. True-positive PET scans were obtained in 24 of 26 CC and false-negative scans in the other 2 (sensitivity 92.3%). The PET scan was true-negative in 18 of 20 controls and in all 8 benign biliary lesions (specificity 92.9%). Visual and semiquantitative evaluation using tumor/non-tumor ratios were equally accurate (accuracy 92.6%) whereas evaluation by standardized uptake value revealed lower accuracy (P <.05). Regional or hepatoduodenal lymph node metastases were detected with PET in only 2 of 15 cases whereas distant metastases (peritoneal carcinomatosis, pulmonary metastases) were diagnosed in 7 of 10 cases. In conclusion, PET is highly sensitive and specific for the detection and localization of CC. It can be helpful for diagnosis of distant metastases but is not suitable for detection of regional lymph node metastases.
Zachary Goodman - One of the best experts on this subject based on the ideXlab platform.
-
The so-called Bile Duct Adenoma is a peribiliary gland hamartoma.
The American journal of surgical pathology, 1996Co-Authors: Prithi S. Bhathal, Norman R. Hughes, Zachary GoodmanAbstract:The cell phenotype of so-called Bile Duct Adenoma (BDA) was investigated immunohistochemically using monoclonal antibodies to two recently identified antigens (designated D10 and 1F6) extracted from human liver and cultured biliary epithelium. The acini and tubules of BDA consisted of serous and mucous cells that expressed D10 and 1F6. The intrahepatic peribiliary glands of normal liver, comprising intramural mucous glands and extramural tubuloalveolar seromucinous glands, similarly expressed D10 and 1F6 antigens. Antigen 1F6 was present in the cells forming the canals of Hering and normal Bile Ductules but not in interlobular and larger Bile Ducts. Proliferating Bile Ductules associated with large Bile Duct obstruction and alcoholic cirrhosis or the epithelia of the von Meyenberg complex and polycystic liver did not exhibit this combined profile of D10 and 1F6 expression and mucous cells. These findings suggest an origin of BDA from peribiliary glands rather than from Bile Ductules or Ducts. Consistent with this view was our finding that 18 of the 30 BDA were spatially related to a large-calibre Bile Duct. Therefore, BDA, well known for its benign behavior, is a small mass of disorganized but mature peribiliary gland acini and tubules within a variable amount of stroma and should properly be called a peribiliary gland hamartoma.
Ryan M Gill - One of the best experts on this subject based on the ideXlab platform.
-
proliferative index facilitates distinction between benign biliary lesions and intrahepatic cholangiocarcinoma
Human Pathology, 2016Co-Authors: Christos G Tsokos, Gregor Krings, Funda Yilmaz, Linda D Ferrell, Ryan M GillAbstract:Differentiation between benign and malignant lesions of the hepatic biliary tree may pose a diagnostic problem because well-differentiated intrahepatic cholangiocarcinoma may mimic biliary hamartoma, Bile Duct Adenoma, or parenchymal extinction. We evaluated Ki-67 proliferative index and p53 status by immunohistochemical staining to aid in exclusion of cholangiocarcinoma. Fourteen biliary hamartomas, 21 Bile Duct Adenomas, and 11 livers with parenchymal extinction were compared with 26 intrahepatic cholangiocarcinomas (16 well-differentiated and 10 moderately or poorly differentiated tumors). We found an increased proliferative index in intrahepatic cholangiocarcinomas compared with benign biliary lesions (average 23.0% in cholangiocarcinoma versus 1.4% in all benign biliary lesions, n = 26 versus n = 46, P < .001). No difference in average proliferative index was observed between well-differentiated and moderately/poorly differentiated cholangiocarcinomas (average 22.7% versus 23.3%, n = 16 versus n = 10, P = .92). Average proliferation indices of benign biliary lesions were uniformly low (biliary hamartoma, 1.2%; Bile Duct Adenoma, 2%; parenchymal extinction, 0.5%). Most cholangiocarcinomas (23/26; 88.5%), but none of the benign lesions (0/46; 0%), had proliferative indices greater than 10%. Strong nuclear p53 immunohistochemical staining was only seen in cholangiocarcinomas (9/26; 34.6%) and not in benign biliary lesions (0/46; 0%), although many of the benign lesions showed weak to moderate staining. Immunohistochemical staining for Ki-67 facilitates distinction between benign and malignant lesions of the intrahepatic biliary tree, whereas p53 immunohistochemical staining is less helpful.
Jianfeng Yang - One of the best experts on this subject based on the ideXlab platform.
-
intrahepatic Bile Duct Adenoma peribiliary gland hamartoma a case report and review of literature
International Journal of Clinical and Experimental Pathology, 2015Co-Authors: Jianguo Wei, Dongmei Zhang, Jianfeng YangAbstract:Bile Duct Adenoma (BDA) is a comparatively rare disease and there are relatively few reported cases in the English-language literature. Herein, we present a 63-year-old woman, who was incidentally found to have a liver-occupying lesion during a routine medical examination. Ultrasonography suggested "quick wash-in and wash-out" sign with an obvious nodular enhancement in the peripheral of the right intrahepatic nodular. Computed tomography revealed a 33 mm×25 mm×28 mm mass in the right hepatic segment. The patient underwent a liver tumor resection. Histological examination showed that the tumor was consisted of small heterogeneous tubular Ducts with fibrous tissues and several inflammatory cells, without cell atypia and mitotic activity. Immunohistochemically, the tumor cells were positive for CK19, CK7, CD56 and CD10. The final histopathological diagnosis was intrahepatic BDA.
Regine Kluge - One of the best experts on this subject based on the ideXlab platform.
-
positron emission tomography with 18f fluoro 2 deoxy d glucose for diagnosis and staging of Bile Duct cancer
Hepatology, 2001Co-Authors: Regine Kluge, Frank Schmidt, Karel Caca, Henryk Barthel, Swen Hesse, Peter Georgi, Anita Seese, Dominik Huster, Frieder BerrAbstract:Malignant tumors with high glucose metabolic rates accumulate [18F]-fluorodeoxyglucose (FDG), a positron emitting tracer. The aim of this study was to evaluate FDG positron emission tomography (PET) for detection and staging of human cholangiocarcinoma (CC). Patients with adenocarcinoma of the biliary tree (n = 26), with benign lesions of the Bile Ducts (n = 8), and 20 control patients underwent FDG-PET (370 MBq [18F]-FDG, Siemens ECAT EXACT HR+). In a blinded fashion, 4 independent experts evaluated the PET scans visually and semiquantitatively using the standardized uptake value and a tumor/non-tumor ratio. All adenocarcinomas and benign lesions (sclerosing cholangitis, Bile Duct Adenoma, Caroli's disease) were histologically proven and imaged by magnetic resonance imaging and endoscopic retrograde cholangioscopy. True-positive PET scans were obtained in 24 of 26 CC and false-negative scans in the other 2 (sensitivity 92.3%). The PET scan was true-negative in 18 of 20 controls and in all 8 benign biliary lesions (specificity 92.9%). Visual and semiquantitative evaluation using tumor/non-tumor ratios were equally accurate (accuracy 92.6%) whereas evaluation by standardized uptake value revealed lower accuracy (P < .05). Regional or hepatoduodenal lymph node metastases were detected with PET in only 2 of 15 cases whereas distant metastases (peritoneal carcinomatosis, pulmonary metastases) were diagnosed in 7 of 10 cases. In conclusion, PET is highly sensitive and specific for the detection and localization of CC. It can be helpful for diagnosis of distant metastases but is not suitable for detection of regional lymph node metastases. (HEPATOLOGY 2001;33:1029-1035.)
-
positron emission tomography with 18f fluoro 2 deoxy d glucose for diagnosis and staging of Bile Duct cancer
Annual Meeting of the American Gastroenterological Association, 2001Co-Authors: Regine Kluge, Frank Schmidt, Karel Caca, Henryk Barthel, Swen Hesse, Peter Georgi, Anita Seese, Dominik Huster, Frieder BerrAbstract:Malignant tumors with high glucose metabolic rates accumulate [18F]-fluorodeoxyglucose (FDG), a positron emitting tracer. The aim of this study was to evaluate FDG positron emission tomography (PET) for detection and staging of human cholangiocarcinoma (CC). Patients with adenocarcinoma of the biliary tree (n = 26), with benign lesions of the Bile Ducts (n = 8), and 20 control patients underwent FDG-PET (370 MBq [18F]-FDG, Siemens ECAT EXACT HR + ). In a blinded fashion, 4 independent experts evaluated the PET scans visually and semiquantitatively using the standardized uptake value and a tumor/non-tumor ratio. All adenocarcinomas and benign lesions (sclerosing cholangitis, Bile Duct Adenoma, Caroli's disease) were histologically proven and imaged by magnetic resonance imaging and endoscopic retrograde cholangioscopy. True-positive PET scans were obtained in 24 of 26 CC and false-negative scans in the other 2 (sensitivity 92.3%). The PET scan was true-negative in 18 of 20 controls and in all 8 benign biliary lesions (specificity 92.9%). Visual and semiquantitative evaluation using tumor/non-tumor ratios were equally accurate (accuracy 92.6%) whereas evaluation by standardized uptake value revealed lower accuracy (P <.05). Regional or hepatoduodenal lymph node metastases were detected with PET in only 2 of 15 cases whereas distant metastases (peritoneal carcinomatosis, pulmonary metastases) were diagnosed in 7 of 10 cases. In conclusion, PET is highly sensitive and specific for the detection and localization of CC. It can be helpful for diagnosis of distant metastases but is not suitable for detection of regional lymph node metastases.